Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16455040 | 0.76 | — | — | |
| SCHEMBL685523 | 0.71 | GAA (0.34) | — | |
| SCHEMBL680166 | 0.70 | — | — | |
| SCHEMBL16577288 | 0.70 | — | — | |
| SCHEMBL15206727 | 0.68 | — | — | |
| SCHEMBL16377493 | 0.62 | LMNA (0.33) | — | |
| SCHEMBL12125884 | 0.61 | BCHE (0.31) | — | |
| SCHEMBL12672904 | 0.61 | CRACR2A (0.38) | — | |
| SCHEMBL16132328 | 0.59 | SSTR1 (0.30) | — | |
| SCHEMBL12245338 | 0.59 | CACNA1H (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9605004-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2017-03-28 | — | — | US | disclosed |
| US-9605004-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2017-03-28 | — | — | US | disclosed |
| US-20160168126-A1 | CHEMICAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2016-06-16 | — | — | US | disclosed |
| US-20160159819-A1 | CHEMICAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168126-A1 | CHEMICAL COMPOUNDS | RDX, CBR3, RRS1 | CNR1 788/4885CNR2 2137/4885 |
| US-20160159819-A1 | CHEMICAL COMPOUNDS | RDX, CBR3, RRS1 | CNR1 930/4885CNR2 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.